GlobalData»

Pharmaceutical companies yet to see success in the tauopathies space have a range of strategies

The company's latest report states that, given the vast range of unmet needs in neurodegenerative

Akiko Fukui, MSc, Healthcare Analyst for GlobalData, explains: "Manufacturers are particularly pursuing

"In addition to targeting multiple indications, another ongoing trend is pursuing multiple compounds in a

A very common strategy in the tauopathies market is that companies are entering into collaborations

Fukui adds: "The discovery stages of potential tauopathy treatments are commonly conducted by small